# US 2013/0252233 A1 · Prediction of antiviral therapy response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252233 A1
- Document ID: US20130252233A1
- Status: Published application
- Kind: A1
- Application number: 13/890,482
- Filed: 2013-05-09
- Published: 2013-09-26
- Earliest claimed: 2008-08-27
- Assignees: Research Corporation; Novartis Florschungsstiftung, Zweigniederlassung friedrich Mischer Institute for Biomedical
- Inventors: Witold Filipowicz; Markus Heim; Magdalena Filipowicz; Jacek Krol; Ilona Markiewicz
- Web page: https://patentgrep.com/patent/US20130252233A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The application relates to methods for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method using miRNA, e.g. miR-122 or miR-296-5p, for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination.

## Claims

### Claim 1

A method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, the method comprising:
(a) analysing a sample from the subject for the level of expression of a miRNA and,
(b) comparing the level of expression of said miRNA in the sample from the subject to the levels of said miRNA in a control sample.

### Claim 2 (depends on 1)

The method of claim 1 wherein the miRNA is miR122 and wherein a lower level of miR-122 in the sample from the subject as compared to the level of miR-122 in the control sample indicate that the subject is not likely to be responsive to said antiviral therapy.

### Claim 3 (depends on 1)

The method of claim 1 wherein the miRNA is miR-296-5p and wherein a higher level of miR-296-5p in the sample from the subject as compared to the level of miR-296-5p in the control sample indicate that the subject is not likely to be responsive to said antiviral therapy.

### Claim 4 (depends on 1)

The method of claim 1 wherein an unaltered or elevated level of miR-122, and/or an unaltered or lowered level of miR-296-5p, respectively, in the sample from the subject as compared to the level of miR-122, and/or miR-296-5p, respectively, in the control sample indicate that the subject is likely to be responsive to said antiviral therapy.

### Claim 5 (depends on 1)

The method of claim 1 wherein the antiviral therapy includes pegylated IFNα (pegIFNα), optionally combined with ribavirin.

### Claim 6 (depends on 1)

The method of claim 1 wherein the viral infection is Hepatitis B virus or Hepatitis C virus infection.

### Claim 7 (depends on 4)

The method of claim 4 wherein the virus is Hepatitis C virus.

### Claim 8 (depends on 1)

The method of claim 1 wherein the sample comprises liver tissue.

### Claim 9 (depends on 1)

The method of claim 1 wherein the expression of genes, which might be predictive of the subject's response to therapy, is also analysed.

### Claim 10 (depends on 9)

The method of claim 9 wherein gene expression is determined by measuring the amount of mRNA gene transcript in the sample, or the amount of cDNA derived from said mRNA.

### Claim 11 (depends on 9)

The method of claim 9 wherein gene expression is determined by measuring the amount of peptide or polypeptide encoded by the gene in the sample.

### Claim 12 (depends on 11)

The method of claim 11 wherein the amount of peptide or polypeptide is determined using a specific binding molecule.

### Claim 13 (depends on 1)

The method of claim 1 wherein the subject is human.

### Claim 14 (depends on 1)

A kit for performing the method of claim 1 comprising:
(i) means for analysing in a sample from a subject the level of expression of a miRNA, e.g. miR-122 or miR-296-5p; and, optionally,
(ii) means for comparing the level of said miRNA, e.g. miR-122 or miR-296-5p, in the sample from the subject to the levels of said miRNA, e.g. miR-122 or miR-296-5p, in a control sample.

### Claim 15 (depends on 14)

The kit of claim 14 further comprising means for analysing the expression of at least one gene which might be predictive of the subject's response to therapy, eventually comprising one or more specific binding molecules that can target molecules representative of said at least one gene which might be predictive of the subject's response to therapy, wherein said specific binding molecule is an oligonucleotide probe, antibody, or aptamer; and, optionally, means for comparing expression of the genes in the sample to expression of the same genes in a control sample.
